Company / Cost of Revenue
ENDONOVO THERAPEUTICS, INC. Cost of Revenue History
FY2014-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$10.0K
FY2022
5-year range
$10.0K / $93.4K
FY2018-FY2022
Trend
-33.3%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cost of Revenue has declined for 3 consecutive years, from $93,385 in FY2019 to $9,990 in FY2022.
Based on SEC 10-K filings.
$9,990 in FY2022 with a 3-year CAGR of -52.5%.
Improved from $65,369 to $9,990 over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -52.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- ENDONOVO THERAPEUTICS, INC.'s cost of revenue has declined for 3 consecutive years.
- 3-year CAGR of -52.5%, indicating a declining trend.
- In FY2022, cost of revenue decreased 33.3% year-over-year.
- Peak cost of revenue was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score -76.54 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $10.0K | -33.3% |
| FY2021 | $15.0K | -77.1% |
| FY2020 | $65.4K | -30.0% |
| FY2019 | $93.4K | +622.2% |
| FY2018 | $12.9K | - |
| FY2016 | - | - |
| FY2015 | $2.2K | -86.0% |
| FY2014 | $15.5K | - |
| FY2011 | - | - |
As of FY2022 · SEC 10-K · Updated Jun 29, 2026